Navigation Links
Study shows benefit of new maintenance therapy for multiple myeloma
Date:5/11/2012

Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients.

Unfortunately, multiple myeloma continues to progress even after a transplant. A study published today in the New England Journal of Medicine offers promising news about a new long-term therapy, lenalidomide, that can be used after transplantation to slow down the progression of the disease.

Thomas Shea, MD, Director of the Bone Marrow and Stem Cell Transplant Program and Associate Director for Outreach Programs at UNC Lineberger and Don Gabriel, MD, Professor of Medicine in the division of hematology/oncology, were both co-authors on the clinical trial, which measured the effect of maintenance lenalidomide therapy on disease-free progression after transplant.

The phase 3 study demonstrated that maintenance therapy with lenalidomide, an oral drug that can be taken for many months or even years, is associated with significant improvement in outcomes for patients with newly diagnosed myeloma who have undergone a transplant. The probability of surviving free of disease progression (the primary end point) for three years was 59 percent in the lenalidomide group, as compared with 35 percent in the placebo group.

"The results of this trial will change our treatment of multiple myeloma patients," said Dr. Shea.

"While lenalidomide has some risks, including an increase in people developing second cancers, it generally appears to be well-tolerated when given long-term and was associated with a delay in time to progression of the myeloma as well as an improvement in overall survival" he added.

Shea noted that another study in France showed similar improvement in delaying progression of the myeloma following transplant, but did not improve how long patients lived after their transplant compared to those receiving a placebo. Additional studies need to be conducted and longer follow-up of the current studies will need to be undertaken to confirm whether there is a real survival benefit of lenalidomide therapy for these patients.


'/>"/>
Contact: Ellen de Graffenreid
edegraff@med.unc.edu
919-962-3405
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. First, Second Kidney Transplants Have Similar Success: Study
2. Oxygen Therapy Slows Type 1 Diabetes in Mice, Study Says
3. Email Vacations Boost Job Productivity, Lower Stress: Study
4. Stem Cell Study Shows Promising Results Against Heart Failure
5. Fitness in Middle Age Lowers Medical Costs Later: Study
6. Smell Tests Dont Predict Alzheimers, Study Finds
7. Only Half of Meds Taken by Kids Have Adequate Safety Info: Study
8. OHSU study: Misdiagnosis of MS is costing health system millions per year
9. Evolution May Explain Runners High, Study Says
10. Infection Causes 1 in 6 Cancers Worldwide: Study
11. Wheelchair Breakdowns on the Rise, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Fresh Wave® IAQ today announced the ... solution for colleges and universities at the APPA 2017 Annual Conference and ... and tobacco smoke odors without the use of harsh chemicals, Fresh Wave IAQ Smoke ...
(Date:7/21/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has written a ... and pleads with world leaders to be more open about positive changes. Yisrayl says the ... there is a peaceful and positive way to solve all; yes, all issues, and he ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... West Dermatology ... Tuantu Doan Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s ... years of experience in dermatology, skin cancer , and more. She graduated from ...
(Date:7/20/2017)... Va. (PRWEB) , ... July 20, 2017 , ... ... McCarter, MD, has joined JenCare Senior Medical Center as Richmond Chief Medical ... Virginia School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for the ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... telemedicine platform, in which their iMedSecure™ comes included with each system installation. ... live images to remote participants for real-time collaboration and immediate decision-making requirements. ...
Breaking Medicine News(10 mins):
(Date:7/21/2017)... -- Endo International plc (NASDAQ: ENDP ) today ... manufacturing network, the Company will be ceasing operations and ... Huntsville, Alabama . The closure of the facilities ... to 18 months. The Huntsville ... products and these restructuring actions are intended to better ...
(Date:7/20/2017)... -- Prime Therapeutics LLC (Prime) released this statement from its Chief ... for Clinical and Economic Review,s (ICER) public meeting ... of abuse-deterrent formulations (ADF) of opioids. Prime was the sole ... "The ICER data ... use of abuse-deterrent formulations (ADF) in opioids in terms of ...
(Date:7/17/2017)... , July 17, 2017  MedX Holdings, Inc., ... medical testing, strengthening and rehabilitation equipment, today announced the ... Program. MedX is considered the gold standard for the ... in specialized medical strengthening equipment. ... lease with the physician or practice who prescribe the ...
Breaking Medicine Technology: